Applications of Metabolomics for Kidney Disease Research: From biomarkers to therapeutic targets

por Wettersten, Hiromi I., Weiss, Robert H.
Publicado 2013

Inhibition of PPARα Induces Cell Cycle Arrest and Apoptosis, and Synergizes with Glycolysis Inhibition in Kidney Cancer Cells

por Abu Aboud, Omran, Wettersten, Hiromi I., Weiss, Robert H.
Publicado 2013

Small-molecule inhibitors of p21 as novel therapeutics for chemotherapy-resistant kidney cancer

por Liu, Ruiwu, Wettersten, Hiromi I., Park, See-Hyoung, Weiss, Robert H.
Publicado en Future Med Chem (2013)

Specific Inhibition of the Nuclear Exporter Exportin-1 Attenuates Kidney Cancer Growth

por Wettersten, Hiromi I., Landesman, Yosef, Friedlander, Sharon, Shacham, Sharon, Kauffman, Michael, Weiss, Robert H.
Publicado en PLoS One (2014)

From bead to flask: Synthesis of a complex β-amido-amide for probe-development studies

por Martin, Kevin S, Soldi, Cristian, Candee, Kellan N, Wettersten, Hiromi I, Weiss, Robert H, Shaw, Jared T
Publicado 2013

Proapoptotic PUMA targets stem-like breast cancer cells to suppress metastasis

por Sun, Qi, Lesperance, Jacqueline, Wettersten, Hiromi, Luterstein, Elaine, DeRose, Yoko S., Welm, Alana, Cheresh, David A., Desgrosellier, Jay S.
Publicado en J Clin Invest (2017)

A novel p21 attenuator which is structurally related to sorafenib

por Wettersten, Hiromi I., Hee Hwang, Sung, Li, Cuiwen, Shiu, Eunice Y., Wecksler, Aaron T., Hammock, Bruce D., Weiss, Robert H.
Publicado 2013

Novel inhibitors of nuclear transport cause cell cycle arrest and decrease cyst growth in ADPKD associated with decreased CDK4 levels

por Tan, Matthew, Wettersten, Hiromi I., Chu, Kristy, Huso, David L., Watnick, Terry, Friedlander, Sharon, Landesman, Yosef, Weiss, Robert H.
Publicado en Am J Physiol Renal Physiol (2014)

Arming tumor-associated macrophages to reverse epithelial cancer progression

por Wettersten, Hiromi I., Weis, Sara M., Pathria, Paulina, Von Schalscha, Tami, Minami, Toshiyuki, Varner, Judith A., Cheresh, David A.
Publicado en Cancer Res (2019)

Biological evaluation of a novel sorafenib analogue, t-CUPM

por Wecksler, Aaron T., Hwang, Sung Hee, Liu, Jun-Yan, Wettersten, Hiromi I., Morisseau, Christophe, Wu, Jian, Weiss, Robert H., Hammock, Bruce D.
Publicado en Cancer Chemother Pharmacol (2014)

Mealtime, Temporal, and Daily Variability of the Human Urinary and Plasma Metabolomes in a Tightly Controlled Environment

por Kim, Kyoungmi, Mall, Christine, Taylor, Sandra L., Hitchcock, Stacie, Zhang, Chen, Wettersten, Hiromi I., Jones, A. Daniel, Chapman, Arlene, Weiss, Robert H.
Publicado 2014

Galectin-3, a druggable vulnerability for KRAS-addicted cancers

por Seguin, Laetitia, Camargo, Maria F., Wettersten, Hiromi I., Kato, Shumei, Desgrosellier, Jay S., von Schalscha, Tami, Elliott, Kathryn C., Cosset, Erika, Lesperance, Jacqueline, Weis, Sara M., Cheresh, David A.
Publicado en Cancer Discov (2017)

Novel Sorafenib-Based Structural Analogues: In Vitro Anticancer Evaluation of t-MTUCB and t-AUCMB

por Wecksler, Aaron T., Hwang, Sung Hee, Wettersten, Hiromi I., Gilda, Jennifer E., Patton, Amy, Leon, Leonardo J., Carraway, Kermit L., Gomes, Aldrin V., Baar, Keith, Weiss, Robert H., Hammock, Bruce D.
Publicado 2014

Inhibiting tryptophan metabolism enhances interferon therapy in kidney cancer

por Trott, Josephine F., Kim, Jeffrey, Aboud, Omran Abu, Wettersten, Hiromi, Stewart, Benjamin, Berryhill, Grace, Uzal, Francisco, Hovey, Russell C., Chen, Ching-Hsien, Anderson, Katie, Graef, Ashley, Sarver, Aaron L, Modiano, Jaime F., Weiss, Robert H.
Publicado en Oncotarget (2016)

Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis

por Zhang, Guodong, Panigrahy, Dipak, Hwang, Sung Hee, Yang, Jun, Mahakian, Lisa M., Wettersten, Hiromi I., Liu, Jun-Yan, Wang, Yanru, Ingham, Elizabeth S., Tam, Sarah, Kieran, Mark W., Weiss, Robert H., Ferrara, Katherine W., Hammock, Bruce D.
Publicado 2014

XPO1 inhibition by selinexor induces potent cytotoxicity against high grade bladder malignancies

por Baek, Han Bit, Lombard, Alan P., Libertini, Stephen J., Fernandez-Rubio, Aleida, Vinall, Ruth, Gandour-Edwards, Regina, Nakagawa, Rachel, Vidallo, Kathleen, Nishida, Kristine, Siddiqui, Salma, Wettersten, Hiromi, Landesman, Yosef, Weiss, Robert H., Ghosh, Paramita M., Mudryj, Maria
Publicado en Oncotarget (2018)

Grade-dependent metabolic reprogramming in kidney cancer revealed by combined proteomics and metabolomics analysis

por Wettersten, Hiromi I., Hakimi, A. Ari, Morin, Dexter, Bianchi, Cristina, Johnstone, Megan E., Donohoe, Dallas R., Trott, Josephine F., Aboud, Omran Abu, Stirdivant, Steven, Neri, Bruce, Wolfert, Robert, Stewart, Benjamin, Perego, Roberto, Hsieh, James J., Weiss, Robert H.
Publicado en Cancer Res (2015)

Epoxy metabolites of docosahexaenoic acid (DHA) inhibit angiogenesis, tumor growth, and metastasis

por Zhang, Guodong, Panigrahy, Dipak, Mahakian, Lisa M., Yang, Jun, Liu, Jun-Yan, Stephen Lee, Kin Sing, Wettersten, Hiromi I., Ulu, Arzu, Hu, Xiaowen, Tam, Sarah, Hwang, Sung Hee, Ingham, Elizabeth S., Kieran, Mark W., Weiss, Robert H., Ferrara, Katherine W., Hammock, Bruce D.
Publicado 2013

Synergistic tumor suppression by combined inhibition of telomerase and CDKN1A

por Gupta, Romi, Dong, Yuying, Solomon, Peter D., Wettersten, Hiromi I., Cheng, Christopher J., Min, JIn-Na, Henson, Jeremy, Dogra, Shaillay Kumar, Hwang, Sung H., Hammock, Bruce D., Zhu, Lihua J., Reddel, Roger R., Saltzman, W. Mark, Weiss, Robert H., Chang, Sandy, Green, Michael R., Wajapeyee, Narendra
Publicado 2014